-
Key inclusion criteria
- At least 18 years of age at time of screening
- Ability to provide informed consent and willing to comply with study procedures (i.e., completion of study outcome questionnaires, participation in intervention if randomised to intervention group)
- New diagnosis of borderline resectable, locally advanced, or metastatic pancreatic cancer commencing chemotherapy
- Life expectancy of at least 6 months from the time of screening as judged by the patient's health care team
- ECOG performance status score of less than or equal to 2
-
Key exclusion criteria
- Patients with neuroendocrine pancreatic cancers
- Patients who have previously had a pancreatic cancer surgical resection
- Patients who have received 2 or more cycles of chemotherapy for pancreatic cancer
- Patients with serious medical or psychiatric conditions that might compromise protocol-based management as judged by the patient's treating healthcare team
- Patients receiving ‘end of life’ care
- Patients who declined or are deemed unsuitable for systemic chemotherapy
- Patients with insufficient cognition to provide consent as judged by the patient's treating healthcare team
- Patients with insufficient knowledge of the English language who do not have a family member that can assist with English translation to facilitate completion of outcome data collection or interviews with the study dietitian
SuperQoL
Locations: Epworth Richmond.
Epworth PI: Mr Daniel Croagh
Jreissati Pancreatic Centre at Epworth
Access this Clinical Trial
Healthcare professionals
General enquiries
Please contact us for more information on 03 9426 8880 or email EH-PancreaticCentre@epworth.org.au